Allen-WintersSWakefieldDGaudioEMooreSBooneKMorrisSet al
Park et al., 2023
492 In another 12-week study, mirikizumab demonstrated promising safety and efficacy in the treatment of UC patients, particularly in terms of endoscopic improvement, clinical remission, and histological remission, with significant therapeutic benefits
Trisulfide bond-mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity
Week 2 to 4: skin and recovery changes
While its parent peptide Thymosin Beta-4 has been extensively studied, TB-500 provides a focused and more pharmacologically viable route for these applications due to its size, stability, and bioactivity